Fundraising Fox
/Companies
Sign in

Cabaletta Bio

NASDAQ: CABA

Radnor, US · Founded 2017 · Delaware corporation · 199 employees on LinkedIn · 3 known investors

Find your way into Cabaletta Bio

Sign up to see every warm intro you have to Cabaletta Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Cabaletta Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases. Its CABA platform and lead CARTA program center on rese-cel, an investigational CD19-CAR T cell therapy being evaluated in trials across rheumatology, neurology, and dermatology.

BiotechHealthtech

Founders & leadership

Cabaletta Bio was founded in 2017 by Steven Nichtberger.

SNSteven Nichtberger
Steven NichtbergerCo-founder, Chairman, & CEOSteven Nichtberger, MD, is the founder, chairman, and founding CEO of Cabaletta Bio, a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. His prior career spans pharmaceuticals, cellular therapy, and medical devices, including senior commercial and strategic leadership at Merck, CEO and President of Tengion, chairman of ControlRad Systems, and partner at GBF Advisors.
DGDan Geffken
Dan GeffkenSenior Financial Advisor2018–2019
AMAnup Marda
Anup MardaChief Financial Officer
MS
Mark SimonNamed on SEC filing

Board

BDBrian Daniels
Brian DanielsBoard directorVenture Partner at 5AM Ventures

Investors · 3

Bain Capital Life Scienceslisted by Bain Capital Life SciencesBoston

How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us

Deerfield Management CompanyreportedNew York

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$88.3M disclosed across 2 rounds · 2018–2019

▶$50MraisedJan 2019 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven NichtbergerExecutive Officer, Director
  • Mark SimonDirector
  • Brian DanielsDirector
  • Dan GeffkenExecutive Officer
Amount sold
$50M
Sales commissions
$1.1M
Placement agents
Cowen and Company, LLC
First sale
Jan 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$38.3MraisedDec 2018 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark SimonDirector
  • Steven NichtbergerExecutive Officer, Director
  • Brian DanielsDirector
  • Dan GeffkenExecutive Officer
Amount sold
$38.3M
First sale
Oct 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$259.1Mvaluation at IPOOct 2019 · $11.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 4

Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

Companies working in the same space as Cabaletta Bio.

Frequently asked questions

What does Cabaletta Bio do?
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases. Its CABA platform and lead CARTA program center on rese-cel, an investigational CD19-CAR T cell therapy being evaluated in trials across rheumatology, neurology, and dermatology.
Who founded Cabaletta Bio?
Cabaletta Bio was founded by Steven Nichtberger in 2017.
Who are Cabaletta Bio's investors?
Cabaletta Bio's investors include 5AM Ventures, Bain Capital Life Sciences, Deerfield Management Company.
How much funding has Cabaletta Bio raised?
Cabaletta Bio has disclosed $88.3M raised across 2 rounds.
Where is Cabaletta Bio headquartered?
Cabaletta Bio is headquartered in Radnor, US.